Antimicrobial resistance (AMR) arises when bacteria, viruses, fungi or parasites evolve the ability to survive drugs that once killed them or stopped their growth. This makes standard treatments less effective, infections harder to control, and increases the risk of severe illness, complications and death.

Research shows AMR develops through genetic changes such as mutations or the acquisition of resistance genes from other microbes. Misuse and overuse of antibiotics in humans, animals and agriculture accelerate this process. Examples include taking antibiotics for viral infections, not completing prescribed courses, using broad spectrum drugs unnecessarily, and routine use of antibiotics in livestock to promote growth or prevent disease in crowded conditions.

Scientists are tracking resistant pathogens like methicillin resistant Staphylococcus aureus, drug resistant tuberculosis and multidrug resistant Gram negative bacteria. These organisms can resist multiple classes of antibiotics, limiting treatment options and driving up healthcare costs. Global surveillance data reveal rising resistance rates in both community and hospital settings.

Current research focuses on understanding resistance mechanisms, improving diagnostics to quickly identify pathogens and their resistance patterns, and developing new antibiotics and alternative therapies. These alternatives include bacteriophages, antimicrobial peptides, antivirulence drugs that disarm pathogens rather than kill them, and strategies that restore the activity of existing antibiotics.

Public health efforts emphasize stewardship to preserve current drugs. This involves more precise prescribing, better infection prevention and control, improved sanitation, vaccination to reduce infection burden, and restricting non essential antibiotic use in agriculture. International collaboration is crucial, as resistant organisms and resistance genes cross borders through travel, trade and the environment.